A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy

Programmed cell death protein-1 (PD-1)/programmed death protein ligand-1 (PD-L1) inhibitors for treatment of a various types of cancers have revolutionized cancer immunotherapy. However, PD-1/PD-L1 inhibitors are associated with a low response rate and are only effective on a small number of patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Xianbin, Lu, Peng, Liu, Chuanxin, Guo, Yuzhu, Yang, Yuying, Peng, Yingying, Wang, Fangyuan, Bo, Zhichao, Dou, Xiaoxin, Shi, Haoyang, Meng, Jingyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985997/
https://www.ncbi.nlm.nih.gov/pubmed/33760188
http://dx.doi.org/10.3892/mmr.2021.12001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985997/
https://www.ncbi.nlm.nih.gov/pubmed/33760188
http://dx.doi.org/10.3892/mmr.2021.12001

Ejemplares similares